Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 42 publications
Radiation Quality and Workflow in NRG GY017: Anti-PD-L1 (Atezolizumab) as an Immune Primer or Concurrently With Radiation Therapy for Node-Positive Locally Advanced Cervical Cancer.
Journal: International journal of radiation oncology, biology, physics
Published: January 12, 2026
Radiation Quality and Workflow in NRG GY017: Anti PD-L1 (Atezolizumab) as an immune primer or concurrently with RT for node positive locally advanced cervical cancer.
Journal: International journal of radiation oncology, biology, physics
Published: January 12, 2026
Image guided brachytherapy quality assurance on NRG GY017 investigating immunotherapy in addition to chemoradiation for locally advanced cervical cancer.
Journal: Brachytherapy
Published: April 04, 2025
Image guided brachytherapy quality assurance on NRG GY017 investigating immunotherapy in addition to chemoradiation for locally advanced cervical cancer.
Journal: Brachytherapy
Published: April 04, 2025
Neoadjuvant or concurrent atezolizumab with chemoradiation for locally advanced cervical cancer: a randomized phase I trial.
Journal: Nature communications
Published: April 17, 2024
An open-label study to determine the maximum tolerated dose of oral ESK-440 administered as a single agent in patients with advanced or metastatic solid tumors.
Journal: Neoplasia (New York, N.Y.)
Published: December 05, 2023
Post hoc analyses of GOG 9923: Does BRCA status affect toxicities?: An NRG oncology study.
Journal: Gynecologic oncology
Published: November 30, 2020
Quality of Life in Adult and Pediatric Patients with Tropomyosin Receptor Kinase Fusion Cancer Receiving Larotrectinib.
Journal: Current problems in cancer
Published: November 09, 2020
Immune Activation in Patients with Locally Advanced Cervical Cancer Treated with Ipilimumab Following Definitive Chemoradiation (GOG-9929).
Journal: Clinical cancer research : an official journal of the American Association for Cancer Research
Published: February 26, 2020
Berzosertib plus gemcitabine versus gemcitabine alone in platinum-resistant high-grade serous ovarian cancer: a multicentre, open-label, randomised, phase 2 trial.
Journal: The Lancet. Oncology
Published: January 02, 2020
Anti-PD-L1 (atezolizumab) as an immune primer and concurrently with extended-field chemoradiotherapy for node-positive locally advanced cervical cancer.
Journal: International journal of gynecological cancer : official journal of the International Gynecological Cancer Society
Published: December 03, 2019
Last Updated: 09/26/2026